{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"description":"If the drug is held for more than 2 weeks due to toxicity, it will be permanently discontinued","groups":[{"description":"Patients who met eligibility criteria and received transplant during the dose-finding phase.","id":"OG000","title":"All Transplant Participants"},{"description":"Patients who met eligibility criteria, received transplant, received 1x10\\^5 cells/kg, and received blinatumomab","id":"OG001","title":"Dose 1"},{"description":"Patients who met eligibility criteria, received transplant, received 1x10\\^6 cells/kg, and received blinatumomab","id":"OG002","title":"Dose 2"},{"description":"Patients who met eligibility criteria, received transplant, received 1x10\\^7 cells/kg, and received blinatumomab","id":"OG003","title":"Dose 3"},{"description":"Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\\^7 cells/kg","id":"OG004","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who met eligibility criteria, received transplant, and received blinatumomab.","reportingStatus":"POSTED","timeFrame":"28 days after receiving first dose of Blinatumomab (up to approximately 7 months post-transplant)","title":"The Number of Patients Experiencing Blinatumomab Permanent Discontinuation Due to Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}